Processing

Please wait...

Settings

Settings

Goto Application

1. WO2005087253 - INTERFERON-BETA FOR ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS
1. Use of an agent selected from:
(a) interferon-β (EFN-β);
(b) an agent that increases IFN-β ©expression; or
(c) a polynucleotide which is capable of expressing (a) or (b); for the manufacture of a medicament for the treatmeα-t of rhinovirus-induced exacerbation of a respiratory disease selected from asihma and chronic obstructive pulomonary disease (COPD), wherein said treatment as by airway delivery of said medicament.

2. A use according to claim 1 wherein said respiratory disease is asthma.

3. A use according to claim 1 wherein said respiratory disease is COPD.

4. A use according to any one of claims 1 to 3 w-herein said agent is EFN-β.

5. A use according to claim 4, wherein the IFN-β comprises the sequence of:
(a) human IFNβ-la (SEQ ID NO: -2); or
(b) human IFNβ-lb (SEQ ID NO: A)

6. A use according to any one of claims 2, 4 and 5 wherein said respiratory disease is asthma and wherein said medicament is a combined preparation for administration of said agent simultaneously, separately or sequentially with an inhaled corticosteroid.

7. A method of treating in an individual a rhinov trus-induced exacerbation of a respiratory disease selected from asthma and COPD comprising airway administration to the individual of an agent selected from the group consisting of:
(a) interferon-β (IFN-β);
(b) an agent that increases IFN-β expression; or
(c) a polynucleotide which is capable of expressing (a) or (b).

8. A method according to claim 7 wherein said agent is IFN-β.

9. A method according to claim 8, wherein the IFNβ comprises the sequence of:
(a) human IFNβ-la (SEQ ID NO: 2); or
(b) human IFNβ-lb (SEQ ED NO: 4)

10. A method according to any one of claims 6 to 8 wherein said respiratory disease is asthma and wherein said medicament is a combined preparation for administration of said agent simultaneously, separately or sequentially with an inhaled corticosteroid.

11. A product for treatment of asthma comprising for simultaneous, separate or sequential airway administration (i) a first agent selected from (a) to (c) as defined in claim 1 and (ii) an inhaled corticosteroid.

12. A product as claimed in claim 13 which is a pharmaceutical composition for aerosol delivery to the airways.

13. A product as claimed in claim 10 or claim 11 wherein said first agent is EFN-β.